CTOs on the Move

Achaogen

www.achaogen.com

 
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are anchored in our work by our key values of integrity, accountability, transparency, scientific rigor and drive. We pride ourselves in creating a work community that is patient-centric, scientifically driven, supportive, and collaborative, and that encourages the diversity of thought leading to great innovation. We are always excited to add people to our dynamic team who thrive in our community and who are driven and motivated to transform the lives of patients.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.achaogen.com
  • 7000 & 6000 Shoreline Court #371
    South San Francisco, CA USA 94080
  • Phone: 650.800.3636

Executives

Name Title Contact Details

Funding

Achaogen raised $116.61M on 06/14/2016

Similar Companies

Synchem

Synchem, Inc. is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flo Health

Flo Health is a developer of Flo, the fastest growing AI-driven women`s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).

Tactical Therapeutics

Tactical Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

Aptevo Therapeutics

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIRâ„¢ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.